Skinvisible, Inc. Issues First Quarter 2001 Investor Update

Apr 11, 2001, 01:00 ET from Skinvisible, Inc.

    LAS VEGAS, April 11 /PRNewswire/ -- Headquartered in Las Vegas, Nevada,
 Skinvisible, Inc. (OTC Bulletin Board:   SKVI) is focused on the development
 of innovative topical polymer-based delivery systems and technologies
 incorporating its patent-pending process for combining hydrophilic and
 hydrophobic polymers into stable water emulsions.  Skinvisible's primary
 marketing objectives are to license its technologies and sell its polymer
 delivery systems to established brand manufacturers and providers of topically
 administered products in the prescription, over-the-counter, cosmetic and
 health & beauty markets.
 
     CORPORATE STRATEGY
 
     Under its long-term strategy, Skinvisible intends to direct its ongoing
 energies and resources towards:
 
     -- Actively expanding its polymer-based delivery system technologies;
     -- Capitalizing on topically administered skincare applications and
        opportunities as identified;
     -- Maximizing efforts for the licensing of its technologies and sale of
        its delivery systems.
 
     It is Skinvisible's goal to be a leader in providing enhanced polymer
 delivery system technologies and product efficiencies for its customers, while
 building shareholder value.
 
     The Company's short-term strategy includes the pursuit of private label
 business opportunities for its antibacterial/antimicrobial hand sanitizer
 formulation in the U.S. and Canada within medical, food service and commercial
 markets.
 
     UPDATES
 
     -- Skinvisible has signed three private label agreements to manufacture
        and supply its antibacterial or antimicrobial hand sanitizer
        formulation with U.S.-based distributors involved in the medical,
        animal-care, and industrial industries;
 
     -- As noted in its January 23, 2001 press release, Skinvisible received
        positive proof that its polymer delivery system is a clear winner in
        enhancing sunscreen performance.  Clinical tests performed by Suncare
        Research Laboratories revealed that Skinvisible's sunscreen formula
        produced successful results which allow labeling as "Very Water
        Resistant with an SPF of 30" in accordance with the FDA's Sunscreen
        Monograph;
 
     -- Skinvisible is currently pursuing discussions with a number of major
        manufacturers of topically applied prescription and over-the-counter
        skincare products, for the inclusion of its polymer delivery systems as
        ingredients to enhance existing product performance and capabilities;
 
     -- Skinvisible is presently holding discussions with two leading sales
        agencies in pursuit of representation of its polymer delivery systems
        to pharmaceutical and over-the-counter skincare manufacturers on the
        West Coast and Eastern U.S.  This will complement Skinvisible's
        existing Midwest representation;
 
     -- During the first fiscal quarter of 2001, Skinvisible's President was
        interviewed by two Wall Street online news services.  These interviews
        can be accessed for audio and text at www.ceocast.com and
        www.wallstreetreporter.com.  The ceocast interview can also be accessed
        directly from Skinvisible's website at www.skinvisible.com.
 
     -- Skinvisible's updated website ( www.skinvisible.com ) was introduced in
        February 2001.  It reflects the Company's current corporate focus and
        strategies, product information, research results and investor
        information for both customers and investors.
 
     This press release sheet contains "forward looking" statements within the
 meaning of Section 21A of the Securities Act of 1933, as amended, and Section
 21E of the Securities Exchange Act of 1934, as amended, and are subject to the
 safe harbors created thereby.  Such statements involve certain risks and
 uncertainties associated with an emerging company.  Actual results could
 differ materially from those projected in the forward looking statements as a
 result of risk factors discussed in Skinvisible's reports that will be on file
 with the US Securities and Exchange Commission (including but not limited to
 the report on Form 10-KSB for the year ended December 31, 2000).
 
     For further information please contact Terry Howlett of Skinvisible, Inc.,
 702-433-7154, or fax, 702-433-7192.
 
 

SOURCE Skinvisible, Inc.
    LAS VEGAS, April 11 /PRNewswire/ -- Headquartered in Las Vegas, Nevada,
 Skinvisible, Inc. (OTC Bulletin Board:   SKVI) is focused on the development
 of innovative topical polymer-based delivery systems and technologies
 incorporating its patent-pending process for combining hydrophilic and
 hydrophobic polymers into stable water emulsions.  Skinvisible's primary
 marketing objectives are to license its technologies and sell its polymer
 delivery systems to established brand manufacturers and providers of topically
 administered products in the prescription, over-the-counter, cosmetic and
 health & beauty markets.
 
     CORPORATE STRATEGY
 
     Under its long-term strategy, Skinvisible intends to direct its ongoing
 energies and resources towards:
 
     -- Actively expanding its polymer-based delivery system technologies;
     -- Capitalizing on topically administered skincare applications and
        opportunities as identified;
     -- Maximizing efforts for the licensing of its technologies and sale of
        its delivery systems.
 
     It is Skinvisible's goal to be a leader in providing enhanced polymer
 delivery system technologies and product efficiencies for its customers, while
 building shareholder value.
 
     The Company's short-term strategy includes the pursuit of private label
 business opportunities for its antibacterial/antimicrobial hand sanitizer
 formulation in the U.S. and Canada within medical, food service and commercial
 markets.
 
     UPDATES
 
     -- Skinvisible has signed three private label agreements to manufacture
        and supply its antibacterial or antimicrobial hand sanitizer
        formulation with U.S.-based distributors involved in the medical,
        animal-care, and industrial industries;
 
     -- As noted in its January 23, 2001 press release, Skinvisible received
        positive proof that its polymer delivery system is a clear winner in
        enhancing sunscreen performance.  Clinical tests performed by Suncare
        Research Laboratories revealed that Skinvisible's sunscreen formula
        produced successful results which allow labeling as "Very Water
        Resistant with an SPF of 30" in accordance with the FDA's Sunscreen
        Monograph;
 
     -- Skinvisible is currently pursuing discussions with a number of major
        manufacturers of topically applied prescription and over-the-counter
        skincare products, for the inclusion of its polymer delivery systems as
        ingredients to enhance existing product performance and capabilities;
 
     -- Skinvisible is presently holding discussions with two leading sales
        agencies in pursuit of representation of its polymer delivery systems
        to pharmaceutical and over-the-counter skincare manufacturers on the
        West Coast and Eastern U.S.  This will complement Skinvisible's
        existing Midwest representation;
 
     -- During the first fiscal quarter of 2001, Skinvisible's President was
        interviewed by two Wall Street online news services.  These interviews
        can be accessed for audio and text at www.ceocast.com and
        www.wallstreetreporter.com.  The ceocast interview can also be accessed
        directly from Skinvisible's website at www.skinvisible.com.
 
     -- Skinvisible's updated website ( www.skinvisible.com ) was introduced in
        February 2001.  It reflects the Company's current corporate focus and
        strategies, product information, research results and investor
        information for both customers and investors.
 
     This press release sheet contains "forward looking" statements within the
 meaning of Section 21A of the Securities Act of 1933, as amended, and Section
 21E of the Securities Exchange Act of 1934, as amended, and are subject to the
 safe harbors created thereby.  Such statements involve certain risks and
 uncertainties associated with an emerging company.  Actual results could
 differ materially from those projected in the forward looking statements as a
 result of risk factors discussed in Skinvisible's reports that will be on file
 with the US Securities and Exchange Commission (including but not limited to
 the report on Form 10-KSB for the year ended December 31, 2000).
 
     For further information please contact Terry Howlett of Skinvisible, Inc.,
 702-433-7154, or fax, 702-433-7192.
 
 SOURCE  Skinvisible, Inc.